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Abstract 
Epidemiological studies provided the first evidence that COX may be involved in the pathogenesis of cancer. In the 
process of carcinogenesis and in the route of intracellular signalling during carcinogenesis, COX-2 expression may be 
a universal phenomenon. In general, COX-2 is up-regulated throughout the tumorigenic process, from early 
hyperplasia to metastatic disease. COX-2 has been reported to be constitutively overexpressed in a variety of 
malignancies and is frequently constitutively elevated in prostate carcinoma. COX-2 was consistently overexpressed 
in premalignant lesions such as prostatic intraepithelial neoplasia, and carcinoma. Cases are described with evolution 
of proliferative inflammatory atrophy of the prostate and prostate carcinoma. The increase of evidence implicating 
COX-2 in cancer has stimulated clinical trials to investigate the efficacy of selective COX-2 inhibitors in individuals 
at risk for human cancer. Regarding prostate carcinoma there is much direct or indirect evidence to support the use of 
COX-2 inhibitors in this disease. Trials using these drugs in familial adenomatous polyposis (FAP) and other patients 
with a high risk of colorectal carcinoma are ongoing. 
Key words 
Prostate cancer; Cyclooxygenase-2; Inhibitors; Pharmacological treatment; Molecular target  
 
 
 
 
  
Introduction 
COX-1 and COX-2 are the two isoforms of cyclooxygenase, which convert arachidonic acid (AA) 
into several eicosanoids such as prostaglandin, thromboxanes and prostacyclin, which participate in 
several normal physiologic processes and inflammation. Whereas COX-1 is constitutively expressed in 
most tissues, COX-2 is an inducible enzyme, stimulated by cytokines, growth factors, oncogenes or 
tumour promoters during inflammation or malignancy. At present, the overexpression pattern of COX-2 
in prostate carcinoma is unresolved. While some reports suggest no significant increase in COX-2 
expression in prostate tumour tissue when com- pared to normal tissues, others have reported a direct 
association of prostate tumour grade and poorly differentiated prostate cancer with COX-2 levels.  
 
Both autocrine and paracrine mechanisms may be responsible for the development and/or progression 
of androgen-independent prostate cancer either directly by stimulation of tumour cell proliferation or 
indirectly by enhanced prostaglandin-regulated local androgen synthesis.  
 
One of the first clues that cyclooxygenase inhibition might be an effective approach to preventing 
cancer came from epidemiological studies. The fact that all non-steroidal anti-inflammatory drugs 
(NSAIDs) in clinical use are cyclooxygenase inhibitors provides a putative link between the inhibition of 
COX activity and the antitumour effect of NSAIDs.  
 
The underlying hypothesis examined is whether COX-2 inhibition would enhance response to 
cytotoxic chemotherapy through inhibition of tumour angiogenesis, promotion of apoptosis or other 
alternative mechanisms.  
COX-2 and prostate carcinoma  
The molecular pathogenesis of prostate cancer has been characterised by alterations of genes and 
proteins involved in proinflammatory pathways. Earlier studies have indicated that one of the prostate 
cancer precursor lesions, proliferative inflammatory atrophy (PIA), shares some molecular traits with 
prostatic intraepithelial neoplasia (PIN), and both of these two early precursor lesions of the prostate 
promote further cancer growth. At this juncture, it is worth recalling the findings from earlier studies 
showing a strong correlation between the levels of AA metabolites and accumulation of proinflammatory 
prostaglandins in prostate carcinogenesis.  
 
COX-2 has been reported to be constitutively over- expressed in a variety of malignancies and is 
frequently constitutively elevated in prostate carcinoma. COX-2 appears to be induced in prostate 
adenocarcinoma cells in dogs [1].  
 
Numerous investigators have evaluated the expression of COX-2 in human prostate cancer with 
conflicting results. Several studies have suggested that COX-2 is commonly overexpressed in prostate 
cancer [2–5]. In contrast, others have found that levels of COX-2 are extremely low or absent in the 
majority of prostate cancers [6, 7].  
 
Several lines of evidence implicate 12-lipoxygenase (12-LOX) as a regulator of human prostate 
cancer [8], and are expressed in the prostate cancer cell lines DU- 145 and PC3 [9]. Platelet-type 12-LOX 
has been shown to regulate growth, metastasis, and angiogenesis of prostate cancer: the 12-LOX pathway 
is a critical regulator of prostate cancer progression and apoptosis, by affecting various proteins regulating 
these processes.  
 
Platelet-type 12-LOX expression was detected in human prostatic tumours and correlated to the 
clinical stage of disease. Human prostate cancer cell lines express the platelet-type isoform of 12-LOX at 
both the mRNA and protein levels, and immunohistochemistry revealed 12-LOX expression in human 
prostate tumours. The enzyme was localised to the plasma mem- brane, cytoplasmic organelles and 
nucleus in non- metastatic cells (PC-3 nm) and to the cytoskeleton and nucleus in metastatic cells (DU-
145) [9].  
  
A study involving the human prostate cancer cell lines PC-3 nm and LNCaP demonstrated up-
regulated COX-2 mRNA expression and increased cell proliferation, total DNA content and endogenous 
prostaglandin E2 (PGE2) production in response to the administration of exogenous dimethylprostaglandin 
E2 [10]. PGE2, as a downstream metabolite of linoleic acid (LA), can increase cell growth as well as the 
enzyme responsible for its own synthesis. Growth of the androgen-unresponsive PC-3 nm human prostate 
cancer cells is stimulated in vitro by the addition of the omega-6 polyunsaturated LA. The growth effects 
of essential fatty acids appear to involve both PGs and leukotrienes, which interconnect with autocrine 
regulation through epidermal growth factor (EGF)-related polypeptides. Studies in many laboratories 
have indicated that the fatty acid composition of the diet, as well as the absolute amounts of fat 
consumed, may influence prostate cancer risk. Prostate cancer incidence rates have been increasing and 
arguments have been postulated that there might be a relationship between the rising cancer risk and an 
increase in the consumption of vegetable oils rich in LA.  
 
As a first approach to the question, a series of experiments in vitro are performed to examine the 
effects of both LA, an n-6 polyunsaturated fatty acid (PUFA), and docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), two n-3 fatty acids, on the growth of human prostate cancer cells [11]. The 
n-3 fatty acids compete with LA and its metabolic product AA for enzymes that regulate eicosanoid 
biosynthesis. When AA is formed from LA, it is largely incorporated into the cell membrane 
phospholipids where it provides a reserve of substrate for eicosanoid biosynthesis. Mobilisation of AA 
involves phospholipase A2, an enzyme that has been shown to be stimulated by EGF [12, 13] (Fig. 1). In 
addition, EGFR has been proposed to be localised with PI3K and ceramide molecules within the plasma 
mem- brane microdomains (caveolae/raft structures), which are enriched in sphingolipids and cholesterol 
[14, 15].  
 
In vitro, like PC-3 nm cells, the DU145 human prostate cancer cell line does not require the presence 
of androgens for its growth; it grows readily in the absence of serum and synthesises both EGF and the 
related polypeptide transforming growth factor α (TGF-α). Both PC-3 nm and DU145 cells possess 
EGF/TFG-α receptors, and it has been suggested that an autocrine loop exists for the regulation of 
prostate cancer cell growth [11] (Fig. 1).  
 
 
 
Fig. 1. Interaction of n-6 fatty acid (LA) and EGF in eicosanoid biosynthesis. DHA and EPA, both n-3 fatty acids, 
compete with LA and its metabolic product AA. Mobilisation of AA involves phospholipase A2, an enzyme that 
stimulates PGE2 synthesis and which has been shown to be stimulated by EGF 
 
The expression of COX-1 is found in prostate tissues as well as in prostate carcinoma samples [16]. 
The expression of COX-2 was modulated by the degree of adenocarcinoma differentiation (Fig. 2): in the 
low and middle groups of adenocarcinoma the expression was strong and there was a very strong 
expression level in the high group of adenocarcinomas. The expression of COX-2 also was high in the 
blood vessels and stromal tissues of prostate carcinoma samples. However, the expressions of COX-2 in 
the blood vessels and stromal tis- sues from benign prostatic hypertrophy, PIN and normal prostate 
samples were at basic levels [16]  
 
 
 
Fig. 2A. In normal prostate gland, growth and maintenance of prostate epithelium depends on growth factors (GF) 
and survival factors (SF) produced by stromal cells. GF and SF are produced as a result of androgen signalling 
through AR. B. During transformation to cancer, the paracrine mechanism of AR action is replaced by an 
emergent autocrine mechanism, whereby cancer cells are less dependent on stromal cell factors. Hypothetical 
COX-2-derived PGE2 potentiates androgen biosynthesis by the 3β-hydroxysteroid dehydrogenase type 2 
(HSD3β2) enzyme and promotes angiogenesis, cell proliferation survival and metastasis. AN, androstenedione; Tt, 
testosterone. C. Both autocrine and paracrine mechanisms may be responsible for the development and/or 
progression of androgen-independent prostate cancer by enhanced prostaglandin-regulated local androgen 
synthesis. COX-2 is a potent stimulator of AR function and the induction of c-Jun expression/phosphorylation 
plays an important role. C-jun exhibits an inhibitory effect on AR protein activity; c-Jun can inhibit the 
transcription activities of the AR promoter 
Moreover, elevated 12-LOX mRNA levels were detected in cancer cells and the expression associated 
with poor differentiation and invasiveness of prostate cancer: approximately one-third of patients showed 
elevated levels of 12-LOX mRNA in prostate cancer tissues com- pared with the matching normal tissues 
[12]. The in- crease of 12-LOX expression in prostate cancer was found to correlate with advanced stage, 
poor differentiation and invasive potential. More importantly, elevation in the expression of this marker in 
prostate cancer patients may predict the disease aggressiveness in this sub- set of patients [17].  
 
The immunohistochemical analysis of human prostate carcinoma reveals that COX-2 expression is 
multi- focal and moderate to strong in the majority of cases. Staining for COX-2 is mild in benign tissue 
as com- pared to prostate carcinoma tissue. Expression of COX- 2 in prostate carcinoma tissue is 
predominantly granular and mostly localised in tumour cells. Interestingly, COX-2 expression in prostate 
carcinoma tissues is greater in the surrounding stromal cells or infiltrating inflammatory cells than in 
tumour cells. This observation raises interesting possibilities about the localisation of COX-2-expressing 
cells in prostate carcinoma. Therefore, stromally derived COX-2 may promote tumour growth by 
producing bioactive prostaglandins which affect carcinoma cells in a paracrine fashion. COX-2 may thus 
be acting as a “landscaping tumour promoter” according to the landscaping model [18].   
Tumour cell invasion and metastasis are complex processes involving multiple host–tumour 
interactions (stromal-epithelium). [12(S)-Hydroxy eicosatetraenoic acid] [12(S)-HETE] can enhance the 
invasive and metastatic potentials of tumour cells by modulating several steps of this complex process. 
There is evidence to suggest that the ability of tumour cells to generate 12(S)-HETE is correlated with 
their metastatic potential [19]. A growing body of recent evidence suggests that 12(S)-HETE may act as a 
second messenger in stimulus–response coupling in some cells.  
 
There are conflicting data regarding whether COX-2 is increased in the epithelial or in the stromal 
component of tumours. COX-2 has been found to be increased in the epithelium of adenomas (i.e., 
colonic epithelium). It has been found that COX-2 expression is increased in the stromal component of 
adenomas [20, 21].  
Mechanisms of cyclooxygenase inhibitors  
The molecular mechanisms by which NSAIDs exhibit anticancer activities are not completely 
understood (Table 1) and it is plausible that COX-2-inhibitor-mediated apoptosis works through both 
COX-2-activity-dependent and -independent pathways.  
Table 1. The molecular mechanisms of cyclooxygenase inhibitor (celecoxib) at cellular levels via COX-2 independent mechanisms 
against prostate cancer 
The molecular mechanisms of celecoxib 
 
 Caused an increase in the number of cells at the G1–S-phase transition point with a trend toward accumulation of more cells in 
the G1 phase and a corresponding decrease in the percentage of cells in the S phase [29, 30]. 
 Induces cell cycle arrest at the G1–S-phase transition point and modifies cell cycle regulatory proteins such as cyclin D1, 
retinoblastoma (Rb), phosphorylated Rb, Cyclin E, p27KIP1 and p21WAF1/CIP1 [74]. 
 Perturb intracellular calcium by inhibiting endoplasmic reticulum Ca2+ -ATPases [75]. 
 Blocks Akt signalling by inhibiting PDK-1 kinase activity [25–29]. 
 Enhanced expression and phosphorylation of c-Jun in LNCaP cells. Overexpression of c-Jun inhibited the AR promoter [33]. 
 Inhibited the expression of androgen up-regulated genes [33]. 
 Inhibited AR-induced gene expression and AR promoter activity at the transcription level [36]. 
 Overexpressed c-Jun by the NSAIDs not only inhibited the function of AR but also directly repressed AR expression at the 
transcription level [34–37]. 
 Induced apoptosis in prostate cancer cells is caspase-3 and -9 mediated [63]. 
 Induced apoptosis was associated with down-regulation of COX-2, nuclear factor kBp65, and with activation of peroxisome 
proliferator-activated receptor ã, apoptosis activating factor-1 and caspase-3 [31, 32]. 
 Inhibited cancer cell growth and mediated protein–protein interactions between heat shock protein 70 (HSP70) and p53 at low 
doses [76]. 
 
 
The biochemical mechanism underlying COX-2-inhibitor-induced apoptosis, however, remains 
elusive. At least three distinct mechanisms have been proposed: first, NSAID treatment of cells resulted 
in an increase in AA that, in turn, stimulated the production of ceramide, a known death signal, by 
activating neutral sphingomyelinase [22]; second, the COX-2 inhibitors have been reported to sensitise 
prostate cancer cells to apoptosis by down- regulating the anti-apoptotic protein Bcl-2 [23, 24]; third, a 
study shows the involvement of a COX-2-independent pathway during the apoptosis signalling [25]. 
 
 Celecoxib induces apoptosis, in part, by blocking the activation of the antiapoptotic kinase Akt (also 
called protein kinase B). The evidence from laboratories has demonstrated the involvement of molecular 
targets other than COX-2 in celecoxib-mediated in vitro antiproliferative effects in prostate [25–28]; the 
3-phosphoinosi- tide-dependent protein kinase-1 (PDK-1)/Akt signalling pathway represents a major 
COX-2-independent mechanism by which celecoxib exerts in vivo antiproliferative effects against 
prostate tumours [29]. Among various putative pathways reported in the literature, blockade of Akt 
signalling is especially noteworthy [26–28]. 
  
It is well documented that PDK-1/Akt signalling plays a central role in regulating cancer cell survival 
and proliferation by affecting the phosphorylation status of a plethora of downstream effectors that are 
either PDK-1 or Akt substrates [30]. Consequently, blockade of this signalling cascade leads to growth 
inhibition by cell cycle arrest and/or apoptosis in malignant cells.  
 
Moreover, celecoxib inhibits adenocarcinoma of the transgenic adenocarcinoma of mouse prostate 
(TRAMP) in a dose-dependent manner, and thus limits the growth of metastatic prostate cancer: 
immunohistochemical detection of proinflammatory protein, NF- κBp65 and COX-2 indicate down-
regulation by celecoxib. Suppression of the above proinflammatory proteins was associated with a higher 
rate of apoptosis and reduced tumour growth [31].  
 
Earlier studies on immunohistochemical detection of NF- κ in tissues from human prostatectomy 
demonstrated overexpression of active subunit of NF- κBp65 [32].  
 
Observations strongly indicate a correlation in the down-regulation of COX-2 with targets such as 
NF- κBp65 that makes cells susceptible to the actions of apoptosis-inducing mechanisms that are believed 
to be simultaneously activated by celecoxib.  
 
In the other way, some reports strongly suggest that NSAIDs are potent inhibitors of androgen 
receptor (AR) function and that the induction of c-Jun expression/phosphorylation [33] plays an important 
role in mediating their effects. Previous studies [34–37] demonstrated that c-Jun exhibits an inhibitory 
effect on AR protein activity. In addition, c-Jun can inhibit the transcription activities of the AR promoter 
[33]. c-Jun is a component of AP-1 protein complex and a member of the basic leucine zipper family of 
sequence-specific dimeric DNA-binding proteins. Stimulated overexpression of c- Jun protein can inhibit 
the function of the AR [34–37]. The transactivation functions of the AR as well as other steroid receptors 
can be affected by c-Jun. The interaction between the AR and c-Jun is mediated through the DNA- and 
ligand-binding domains of AR and the leucine zipper region of c-Jun that may affect transcriptional 
function of the AR [36]. Other studies indicate that the transcriptional interference between AR and c- Jun 
is partly mediated through competition for intracellular cAMP-responsive element binding protein [37], 
which serves as an integrator/coactivator for AR trans- activation activities.  
Clinical prospects and future directions for COX-2 inhibitors  
The increasing evidence implicating COX-2 in cancer has stimulated clinical trials to investigate the 
efficacy of selective COX-2 inhibitors in individuals at risk for human cancer. Treatment with COX-2 
inhibitors has been shown to reduce the size and number of polyps in familial adenomatous polyposis 
(FAP) patients, and is currently being evaluated for efficacy in preventing sporadic colorectal adenomas 
[38, 39]. There is enough reviewed evidence that aberrant COX-2 expression is also associated with 
breast cancer: selective COX-2 inhibitors have proved effective in preventing experimental breast cancer 
[40].  
 
Some, but not all, studies suggest that COX-2 is overexpressed in primary human prostate cancers and 
in human prostate cancer cell lines [41–45]. Selective COX-2 inhibitors induce apoptosis of human 
prostate cancer cells in vitro and in vivo.  
 
Attending to prostate carcinoma, there is much direct or indirect evidence to support the use of COX-2 
inhibitors in this disease. Inhibition of cyclooxygenase by traditional NSAIDs and other selective 
inhibitors of the proinflammatory COX-2 isoform may also prove to have chemopreventive efficacy in 
prostate.  
 
The results of case-control studies suggest that men who regularly took NSAIDs may have a reduced 
relative risk of prostate cancer, particularly for advanced cases of the disease [46]. Limited 
epidemiological studies suggest that NSAID use is associated with reduced risk of prostate cancer [46–
48]. Elevated levels of PGE2 and AA metabolism are seen in benign and malignant human prostate 
tumour cells, and NSAIDs inhibit prostate tumour cell growth [49–52].  
  
Two NSAID derivatives that have lost COX inhibitory but retained pro-apoptotic activity are also 
promising chemopreventive agents in prostate: the sulphone metabolite of sulindac most probably 
stimulates apoptosis via inhibition of cyclic GMP phosphodiesterase. This drug was found to inhibit the 
rise of (prostate-specific antigen) PSA in patients with recurring prostate cancer after radical 
prostatectomy [53].  
 
In addition, it has also been shown that the 12-LOX pathway of AA metabolism regulates cell growth, 
through inhibition of cell proliferation, protein regulating apoptosis, transition in the cell cycle and Rb 
protein family members. Inhibition of 12-LOX led to growth inhibition associated with a specific G1 
arrest, followed by induction of apoptosis through caspase and Bcl-mediated mechanisms [54].  
 
As COX-2 is overexpressed in HER-2/neu-positive breast cancer, selective COX-2 inhibitors should 
be evaluated as therapy in the prostate cancer population. Because COX-2-derived PGs may enhance 
aromatase activity, a therapeutic regimen combining a selective COX-2 inhibitor with an aromatase 
inhibitor should be considered. Actually, in some hormone-resistant prostate tumours, glucocorticoid was 
added to complement the treatment with good success. Hormonal therapy with glucocorticoid may 
constitute a basic or first treatment for some prostate carcinoma tumours in patients with an 
adenocarcinoma that has a Gleason score ≥ 8 by including glucocorticoid therapy as soon as the diagnosis 
is confirmed. Transcription of COX-2 is inhibited markedly by glucocorticoid therapy.  
 
NSAIDs have been seen to inhibit NF- κB signalling (Fig. 3) by directly blocking the activity of I κB 
kinase β [55, 56]. Additionally, indomethacin, a non- selective COX inhibitor, can act as a direct ligand 
for peroxisome proliferator activating receptor (PPAR) α and γ, and thus may directly regulate gene 
transcription [57]. The ability of PPARs to bind eicosanoids suggested that PPAR δ might be a target of 
chemopreventive nonsteroidal anti-inflammatory drugs [58–60]. The findings suggest that PPAR δ 
represents a β-catenin/Tcf-4 target with particular importance for chemoprevention. Whereas APC or β-
catenin mutations can result in increased PPAR δ activity, NSAIDs can compensate for this defect by 
suppressing PPAR δ activity and promoting apoptosis. This suppression of PPAR δ is mediated in part by 
the ability of some NSAIDs to directly inhibit the DNA-binding activity of PPAR δ (Figs. 3 and 4).  
 
 
 
Fig. 3A. There is evidence that PGs can modulate cellular pathways by acting directly within the nucleus. Certain 
NSAIDs can activate peroxisome proliferator activated receptor subtypes (PPARα and PPARγ). B. NSAIDs can 
inhibit the activity of IkB kinase β (IKKβ); this leads to antagonism of the NF-κB signalling pathway by blocking 
the destruction of the NF-κB inhibitor IkB, preventing NF-κB from translocating to the nucleus and regulating key 
target genes. C. Other NSAIDs have been shown to inhibit the DNA-binding activity of peroxisome proliferator 
activated receptor subtype (sulindac) 
  
 
 
 
Fig. 4A. The different classes of PGs exert their effects by binding to a G-protein-coupled cell-surface receptor 
leading to changes in the cellular levels of cAMP and Ca2+, or by acting directly within the nucleus. PGE2 works 
by its receptor EP1 (localised to the nuclear envelope) and activation of the receptor leads to change in nuclear 
levels of Ca2+, retinoid X receptor (RXR). Metabolites of PGD2 can transactivate members of the PPAR family of 
nuclear hormone receptors. B. Epidermal growth factor receptor (EGFR), aberrantly expressed in prostate 
carcinoma, can activate cell growth through the RTK/PI3K/AKT pathway. COX-2 inhibitors induce apoptosis by 
blocking AKT activation in prostate cancer cells independently of Bcl-2. Otherwise, overexpression of Her2/neu 
has been implicated in the activation of the AR and in inducing androgen-resistant prostate cancer cell growth. C. 
NSAIDs can decrease the levels of the anti-apoptotic gene bcl-xL, thereby increasing the cellular ratio of 
BAX/bcl-xL. There is also evidence that micro-tubule-interfering agents stimulate COX-2 transcription; 
otherwise, microtubule-interfering agents inhibit Bcl-2 activity by inducing Bcl-2 phosphorylation 
There is also recent evidence that microtubule-interfering agents, including taxanes, stimulate COX-2 
transcription [61]. This could modify the efficacy of this class of drugs. Thus, coadministration of a 
selective COX-2 inhibitor with cytotoxic drugs, such as taxanes, might enhance their anti-cancer activity. 
Induced expression of COX-2 is at least partly responsible for the increased resistance to 
chemotherapeutic drugs. Furthermore, systemic inhibition of COX-2 activity may abrogate this 
resistance, thus opening a new avenue for increasing the efficacy of antitumour drugs against hormone 
refractory prostate cancer (HRPC). Activation of prosurvival pathways mediated through up-regulation of 
inducible enzyme COX-2 due to inflammation or stress appears to be one of the limiting factors in 
reducing the efficacy of chemodrugs and increasing metastatic potentials of established tumours. A 
taxane-containing regimen will be selected for clinical study, because prior work [61] found that this 
chemotherapeutic agent induced COX-2 and prostaglandin biosynthesis. A selective COX-2 inhibitor 
would be expected to prevent the possible negative action of this chemotherapeutic agent. Modulation of 
the Bcl-2 pathway may also contribute to the antitumour effects noted with the nonsteroidal anti- 
inflammatory drugs and COX-2-specific inhibitors [62]. Several agents with preclinical activity in 
prostate cancer have now been demonstrated to modulate Bcl-2. The taxanes inhibit Bcl-2 activity by 
inducing Bcl-2 phosphorylation.  
 
Cytotoxicity of single or combination treatment in- creased apoptosis, which was associated with 
caspase-3 and -9 activation, increased BAD protein, but decreased protein levels of X-linked inhibitor of 
apoptosis protein (XIAP) and Bcl-xL. Overall, a synergistic enhancement of antitumour activity in 
combination treatment was observed in vitro and an additive effect in vivo [63]. These results indicate 
that a combination of cytotoxic drug as taxanes with COX-2 inhibitor has a synergistic effect and 
therefore improves the cytotoxicity of either drug (Fig. 4).  
 
Furthermore, increased resistance to cytotoxic anti- tumour drugs is also known to be dependent on 
associated stromal cells in many tumours. Data presented recently [63] demonstrate that stromal factor 
induced overexpression of COX-2 and thereby increased release of cytoprotective prostacyclin PGI2 in 
prostate carcinoma cells, and may be one of the factors responsible for limiting the efficacy of 
chemodrugs on prostate carcinoma cells. Stromal cells and factors derived from them have been known to 
influence therapeutic response in vivo and reduce cytotoxicity in vitro in a variety of tumours and cell 
types [64]. Some reports document that stromal cells alter expression of cell adhesion molecules, 
integrins, cytokines, chemokines and also cell cycle-related events. In fact it was demonstrated that 
coculture of prostate carcinoma cells (LNCaP) with osteoblasts cells caused an increase in the number of 
prostate cells in G0-G1 and a decrease in S and G2-M phases of cell cycle. This stromal-induced enhanced 
G0-G1 checkpoint control affected the chemosensitivity of prostate cancer cell line to chemodrugs [65].  
 
In the other regard, the EGF receptor is frequently aberrantly expressed in prostate carcinoma [64] and 
has been proposed as a target for treatment of prostate carcinoma [66, 67]. The EGF/EGFR transduction 
pathway has been recognised to play a crucial role in metastatic prostate cancer cells [68, 69]. EGFR and 
its ligands EGF/TGF α appear to participate through autocrine and paracrine loops in prostatic tumour 
growth invasiveness and angiogenic processes by activating MAPK/PI3K and PLCg intracellular 
cascades and so increasing the cellular expression of PKA signalling [70, 71]. The activation of EGFR 
might lead to the negative modulation of apoptotic signals by activating PI3K/AKT survival cascade and 
inhibiting ceramide accumulation [72]. In vitro, simultaneous EGFR inhibitor and nitric oxide re- leasing 
compound might lead to a synergy in the ceramide and reactive oxygen species production, which might 
cause cellular membrane damage of metastatic prostate carcinoma cells [73]. Clinical benefits might 
derive from a regimen that combined a COX-2 inhibitor with an EGF receptor inhibitor (Fig. 4). COX-2 
and EGFR are gaining significant attention as potential chemopreventive agents [77]. Targeting COX-2 
and EGFR separately has shown promising antitumour activity. As both COX-2 and EGFR are involved 
in prostate carcinogenesis, COX-2 and EGFR inhibitors can be used as therapeutic strategies to treat 
prostate carcinoma; combinations of both inhibitors have been reported to show synergistic additive 
effects in preclinical studies [78].  
 
The current trials advance prior preclinical work that implicates synergistic effects of combining COX 
inhibitors with cytotoxic chemotherapy and/or pharmacologic agents. In this way, at cellular levels via 
COX-2 independent mechanisms, celecoxib are capable of inducing cell cycle arrest at the G1-S-phase 
transition [74], perturbing intracellular calcium by inhibiting endoplasmic reticulum Ca
2+
 -ATPases [75], 
inhibiting cancer cell growth and mediating protein-protein interactions between heat shock protein 70 
(HSP70) and p53 at low doses [76]. Recently, there has been evidence of modest biologic activity for 
celecoxib in men with rising PSA levels after radical prostatectomy and/or radiation therapy for prostate 
cancer. A recent study suggests that celecoxib with weekly docetaxel and estramustine is an effective and 
safe treatment for patients with hormone-refractory prostate cancer, but it does not seem to add any 
benefit to docetaxel [79].  
Conclusions  
One of the first clues that cyclooxygenase inhibition might be an effective approach to preventing 
cancer came from epidemiological studies. Preclinical and clinical evidence has established COX-2 as an 
attractive therapeutic or chemopreventive target in the prostate. Inducible COX-2 affects synthesis of 
prostaglandins from AA and is frequently activated during inflammation and carcinogenesis. COX-2 is 
also overexpressed in preneoplastic prostate lesions and inducible prostaglandin synthase is 
overexpressed in prostate carcinoma. It is also notable that epidemiologic data demonstrated a role for 
aspirin in suppressing prostate carcinogenesis.  
 
Taken together, these findings clearly indicate that chronic elevation of COX-2 is pathological and 
suggest that inhibition of COX-2 via pharmacological means or regulation of its expression can limit the 
development or progression of human prostate cancer.  
 
The investigations should be commended for designing and conducting trials which are excellent 
examples of translational research, by addressing whether NSAIDs can be administered in combination 
with chemotherapy. Undoubtedly the potential use of selective COX-2 inhibitors for the treatment of 
prostate cancer will also be investigated.  
 
The ultimate goal of cancer treatment is to specifically prevent the growth of precancerous or 
cancerous cells without affecting normal cells. This is particularly important in chemoprevention and 
treatment of early disease, which typically involves long-term treatment of healthy subjects.  
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